Amantadine, fatigue, and multiple sclerosis.
In a double-blind placebo-controlled crossover study of ten patients with multiple sclerosis, we found amantadine hydrochloride therapy to be effective in improving fatigability in six. Administration of the drug was associated with significantly higher levels of beta-endorphin-beta-lipotropin and responders had significantly higher levels than nonresponders. Lactate levels were significantly higher and pyruvate levels lower in nonresponders. Amantadine given for fatigue to patients with multiple sclerosis is associated with measurable changes in levels of metabolites and peptides in the circulation.
Rosenberg
G A
GA
Department of Neurology, University of New Mexico School of Medicine, Albuquerque 87131.
Appenzeller
O
O
D000547:Amantadine / Q000009:adverse effects / Q000627:therapeutic use*; D004185:Disability Evaluation; D005221:Fatigue / Q000188:drug therapy / Q000209:etiology*; D006801:Humans; D007773:Lactates / Q000097:blood; D019344:Lactic Acid; D009103:Multiple Sclerosis / Q000150:complications* / Q000503:physiopathology; D011773:Pyruvates / Q000097:blood; D019289:Pyruvic Acid; D001615:beta-Endorphin / Q000097:blood; D008083:beta-Lipotropin / Q000097:blood
D007773:Lactates; D011773:Pyruvates; D019344:Lactic Acid; D001615:beta-Endorphin; D019289:Pyruvic Acid; D008083:beta-Lipotropin; D000547:Amantadine